Free Trial
→ Silicon Valley Gold Rush (From Stansberry Research) (Ad)
NASDAQ:ADTX

Aditxt 5/20/2024 Earnings Report

Aditxt logo
$2.08 -0.12 (-5.45%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$2.08 0.00 (-0.24%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings History

Aditxt EPS Results

Actual EPS
-$91,400.00
Consensus EPS
-$33,300.00
Beat/Miss
Missed by -$58,100.00
One Year Ago EPS
N/A

Aditxt Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aditxt Announcement Details

Quarter
Date
5/20/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Aditxt's next earnings date is estimated for Monday, May 19, 2025, based on past reporting schedules.

Conference Call Resources

Aditxt Earnings Headlines

Aditxt (NASDAQ:ADTX) Trading Down 5.5% - Here's What Happened
May 7 at 3:29 AM | americanbankingnews.com
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
May 2, 2025 | businesswire.com
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
May 7, 2025 | Porter & Company (Ad)
Aditxt’s Subsidiary Pearsanta Gets IRB Approval
April 22, 2025 | tipranks.com
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™
April 17, 2025 | businesswire.com
Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis ...
April 15, 2025 | seekingalpha.com
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX), a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

View Aditxt Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles